A new drug called dostarlimab saw astonishing results in a 12-person rectal cancer trial: Every one of the dozen patients went into remission. All the patients were still in remission in a six-month follow-up of the trial as well. Additionally, none of the patients had received chemoradiotherapy or undergone any preventative surgery, and no cases of progression or recurrence were reported during the volunteers' follow-up appointments, according to the study. The drug, sold under GlaxoSmithKline's brand name of Jemperli, has already been approved by the Food and Drug Administration (FDA) in the treatment of certain endometrial cancers. The study was published to The New England J
Hence then, the article about remission seen in every rectal cancer patient in small study of drug was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Remission seen in every rectal cancer patient in small study of drug )